This content is created by Smallcaps Authors. [Author : Imelda Cotton]
Clinical stage immuno-oncology company Imugene (ASX: IMU) will collaborate with global biopharmaceutical company Roche on an Imprinter trial to evaluate the safety and efficacy of lead candidate IMU-201 (PD1-Vaxx) combined with atezolizumab (Tecentriq) for the treatment of non-small cell lung cancer (NSCLC). The open label Phase 1/1b trial is based on B-cell immunotherapy as monotherapy […]
The post Imugene and Roche partner to evaluate PD1-Vaxx with Tecentriq for non-small cell lung cancer appeared first on Small Caps.
from Small Caps https://ift.tt/T8Z1Qpf
إرسال تعليق